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Abstract
Background: Despite the increasing use of pre- and posthydration protocols and low-osmolar instead of
high-osmolar iodine-containing contrast media, the incidence of contrast-induced nephropathy (CIN) is still
significant. There is evidence that contrast media cause ischemia-reperfusion injury of the medulla. Remote
ischemic preconditioning (RIPC) is a non-invasive, safe, and low-cost method to reduce ischemia-reperfusion injury.
Methods: The RIPCIN study is a multicenter, single-blinded, randomized controlled trial in which 76 patients at risk
of CIN will receive standard hydration combined with RIPC or hydration with sham preconditioning. RIPC will be
applied by four cycles of 5 min ischemia and 5 min reperfusion of the forearm by inflating a blood pressure cuff
at 50 mmHg above the actual systolic pressure. The primary outcome measure will be the change in serum
creatinine from baseline to 48 to 72 h after contrast administration.
Discussion: A recent pilot study reported that RIPC reduced the incidence of CIN after coronary angioplasty.
The unusual high incidence of CIN in this study is of concern and limits its generalizability. Therefore, we propose
a randomized controlled trial to study whether RIPC reduces contrast-induced kidney injury in patients at risk for
CIN according to the Dutch guidelines.
Trial registration: Current Controlled Trials ISRCTN76496973
Keywords: Contrast-induced nephropathy, Remote ischemic preconditioning, Acute kidney injury, Pre- and
posthydration, Randomized controlled trial
Background
Iodine-containing contrast media are often used for
diagnostic and therapeutic procedures and their use is
the leading cause of hospital-acquired acute kidney
injury [1]. Prospective studies demonstrate that contrast
media are responsible for approximately 15% of acute
kidney injury cases [2,3]. Despite the increasing use of
pre- and posthydration protocols and low-osmolar instead
of high-osmolar iodine-containing contrast media, the
incidence of contrast-induced acute kidney injury is still sig-
nificant [4,5]. This so called contrast-induced nephropathy
(CIN) is defined as an absolute rise of ≥0.5 mg/dL and/or a
relative increase of ≥25% in serum creatinine compared to
baseline within 48 to 72 h after contrast administration
without an alternative cause of kidney injury [6]. CIN is
strongly associated with morbidity and mortality [7,8]. In
patients with CIN, 8% need dialysis treatment and between
22% and 34% die during the index hospitalization [3,9-11].
In accordance with international guidelines, all patients
who receive iodine-containing contrast are screened for
risk factors of CIN, including measures of renal function
(estimated glomerular filtration rate, based upon the
MDRD formula) [12-15]. High-risk patients receive pre-
and posthydration by saline solution infusion for 4 to 12 h.
Furthermore, 48 to 72 h after contrast administration,
serum creatinine should be measured [16]. Despite the
identification of high-risk patients and the use of hydration
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protocols, the incidence of CIN still varies between 2% and
13% [17-20]. The exact mechanism underlying CIN
remains to be elucidated. There is evidence to suggest that
contrast media have direct toxic effects on the tubular cells
resulting in altered mitochondrial function and apoptosis
[21]. Moreover, ischemia-reperfusion injury of the medulla
has been shown to play an important role [22]. The outer
part of the medulla has an area with a high oxygen demand
and is located at a distance from the vasa recta which sup-
plies the medulla of blood. Contrast-induced vasoconstric-
tion of the vasa recta induces ischemia-reperfusion injury
of the medulla which contributes significantly to the patho-
physiology of CIN. Remote ischemic preconditioning
(RIPC) is a short and harmless discontinuation of blood
supply to particular organs or tissue, followed by reperfu-
sion [23,24]. A preconditioning stimulus is applied before
the onset of prolonged ischemia. In animal models it has
been found to reduce ischemia-reperfusion injury of the
kidney [25]. Although the precise mechanism of RIPC
remains unknown, two major pathways may play a pivotal
role: the humoral and neurogenic pathways. Both are
thought to induce various kinase cascades and eventually
prevent opening of the mitochondrial permeability transi-
tion pore in the target organ, thereby reducing cell death
[26]. A retrospective cohort study by Whittaker et al.
indicated that multiple balloon inflations during coronary
angioplasty (as a remote stimulus) might reduce CIN [27].
Furthermore, a recent pilot study by Er et al. showed that
RIPC reduced CIN in high-risk patients undergoing elect-
ive coronary angiography [28]. However, there was an
unusually high incidence of CIN (40%) in the control
group. The question arises whether protection by RIPC, as
an adjunct to standard preventive measures (that is, hydra-
tion and discontinuation of nephrotoxic drugs), also holds
for patients with a lower risk of CIN. As generalizability of
the results by Er et al. is confined to a selected group of
patients with an unusual high risk of CIN, we propose a
randomized controlled trial to study whether RIPC reduces
contrast-induced kidney injury in patients at risk of CIN
according to the Dutch guideline [14].
Methods/Design
A multicenter, single-blinded, randomized controlled trial
will be performed at the Radboud University Nijmegen
Medical Centre and Slingeland Hospital Doetinchem.
Inclusion will be performed by the physician researcher
after written informed consent.
Study population
A total of 76 patients will be randomized. Sealed enve-
lopes are used to randomly assign consecutive patients
in a 1:1 ratio to receive either sham preconditioning or
RIPC (Figure 1). The study population consists of
patients at risk of CIN according to criteria adopted
from the Dutch guidelines: (1) eGFR <45 mL/min/1.73 m2;
(2) eGFR <60 mL/min/1.73 m2; (3) eGFR <60 mL/min/
1.73 m2 and two additional risk factors (that is, peripheral
vascular disease, heart failure, >75 years of age, anemia,
dehydration, use of diuretics and/or NSAIDs). Patients
undergoing contrast procedures for diagnostic and/or
treatment purposes are eligible. As patients receiving less
than 100 mL of iodinated contrast media may not have an
increased risk of contrast-induced kidney injury, an ex-
pected use of at least 100 mL was used as inclusion
criterion [3,29].
Inclusion criteria
1) Patients undergoing an interventional or diagnostic
radiological procedure in which they receive an
expected >100 mL intravascular contrast including:
 Thoracic and/or abdominal endovascular aortic
repair
 Endovascular aortic repair
 Digital subtraction angiography
 Percutaneous transluminal angioplasty
 Percutaneous intentional extraluminal
revascularization
 Carotic artery stenting
 Percutaneous coiling/embolization procedures
 Computed tomography
2) Patients who comply with the risk criteria for CIN
according to the Dutch guidelines [14]
 Peripheral vascular disease, heart failure, >75 years,
anemia (Ht < 0.39 men and <0.36 women,
dehydration, diuretics and/or NSAID use)
3) Written informed consent.
Exclusion criteria
 Age <18 years
 Hemodialysis or peritoneal dialysis
 Simultaneous participation in another
interventional study
 Percutaneous coiling/embolization procedures
of the kidney
 Impossibility to perform RIPC, due to pathology of
both arms (for example, dystrophy, recent trauma,
chronic wounds)
Study protocol
All participating patients will receive the standard hydra-
tion schedule consisting of an infusion with saline 0.9%
solution 3 to 4 mL/kg/h for 4 h prior to and 4 h after
contrast administration. In patients with congestive
heart failure or MDRD <30 mL/min/1.73 m2 a long
schedule is used with an infusion of saline 0.9% solution
1 mL/kg/h for 12 h prior to and 12 h after the contrast
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administration. Nephrotoxic drugs (for example, metfor-
min and diuretics) are discontinued at least 24 h before
and after contrast administration [14]. Patients in the
experimental group of the study will receive RIPC by
four cycles of ischemia and reperfusion of the forearm
by inflating a blood pressure cuff around the upper arm
at 50 mmHg above the actual systolic pressure during
5 min followed by 5 min of reperfusion. In the control
group, patients receive sham preconditioning by inflating
the blood pressure cuff to 10 mmHg below the actual
diastolic pressure during 5 min followed by 5 min of
reperfusion (four cycles). The time between the last
inflation cycle and the start of the intervention is
planned within 45 min. In the interest of blinding, the
investigator ensures that the inflation pressure is not
visible for both the patient and the (interventional) radi-
ologist. All patients receive Xenetrix 300 (0.6 to 0.85
Osmol/kg H2O), a low osmolar, non-ionic, and hydro-
philic contrast medium [30,31]. Patients will complete a
questionnaire to obtain all relevant baseline characteris-
tics such as age, weight, previous contrast procedures,
diabetes, vascular-related diseases, and (discontinuation
of ) medication. Chart review will be performed to com-
plement and double check this information. Blood and
urine samples are taken at baseline and 4 to 6 h after
contrast administration. A final blood sample is taken 48
to 72 h after contrast administration. According to the
Dutch guidelines, monitoring of renal function in high-
risk patients is recommended within 48 to 72 h after
contrast administration. All samples will be number
coded before analysis to ensure blinding of the inde-
pendent investigator performing the analyses.
Primary endpoint
The primary endpoint is change in serum creatinine
form baseline to serum creatinine within 48 to 72 h after
contrast administration.
Secondary endpoint
The secondary endpoints are the incidence of CIN
(defined as an absolute rise of ≥0.5 mg/dL or a relative
increase of ≥25% in serum creatinine over baseline
within 48 to 72 h after contrast administration), rehospi-
talization, hemodialysis, and mortality within 6 weeks
after contrast administration.
Ethics, informed consent
An independent ethics committee, the Central Committee
on Research involving Human Subjects, Arnhem-
Nijmegen, approved the protocol. Oral and written
informed consent from the patient will be obtained prior
to inclusion.
Adverse events
Although RIPC by repeated insufflations of a blood
pressure cuff around the upper arm is considered safe,
serious adverse events possibly related to the application
of RIPC will be reported to the ethical committee.
Mild adverse events are: transient discomfort due to
Patients at risk of CIN - according to 
the Dutch guideline - scheduled for 
a contrast-procedure
Randomisation n = 76
Sham preconditioning n = 38
Follow up:
48-72 hours after contrast 
administration
RIPC n = 38
Follow up:
48-72 hours after contrast 
administration
Figure 1 Study flow chart. Legend: n.a.
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compression and/or ischemia and the formation of
ecchymosis (upper arm) or petechia (lower arm).
Power analysis
In this randomized study, the change of serum creatinine
from baseline to 48 to 72 h after contrast administration
will be compared between the experimental and control
group. Using serum creatinine change as continuous
response variable increases the power of the study. In a
previous retrospective cohort study at our center includ-
ing 2,169 patients at risk for contrast-induced nephropa-
thy, serum creatinine values decreased from 120 μmol/L
at baseline to 118 μmol/L at 48 to 72 h after contrast
administration due to adequate hydration protocols [17].
This mean change in serum creatinine (-2 μmol/L)
was normally distributed with a standard deviation of
23 μmol/L. Based on existing evidence we assume
that RIPC with hydration may provide a further de-
crease in mean serum creatinine from baseline to 48
to 72 h of approximately 14 μmol/L as compared to
hydration only. This corresponds with approximately
60% of the effect that was found by Er et al. [28]. If
the true difference in the experimental and control
means is 14 μmol/L, we will need to study 34 experi-
mental and 34 controls to be able to reject the null
hypothesis with a power of 0.80 and an alpha of 0.05
calculated with a one-sided independent t-test. Based
on existing animal [25] and human studies [32,33]
investigating the influence of RIPC on renal ischemia-
reperfusion injury, we assume that RIPC does not
negatively affect renal function. Therefore, one-sided
testing would be appropriate for this study. Expected
lost to follow-up (for example, blood sampling not
realized between 48 to 72 h) is approximately 5%. For
this reason 38 patients will be included in both the
experimental and control arm.
Statistical analysis
The analysis will be performed on the basis of intention-
to-treat principles. Student’s t-test will be used to com-
pare normally distributed variables, and Mann-Whitney
U test will be used to compare not-normally distributed
continuous data. Categorical variables will be compared
with the chi-square test. If univariable analysis reveals a
significant difference in baseline characteristics, then a
multivariable linear regression analysis will be used to
assess its impact on the primary outcome measure (that
is, change in serum creatinine between baseline and 48
to 72 h after contrast administration). A subgroup ana-
lysis will be performed to assess whether the impact of
RIPC on the primary outcome measure is affected by
the Mehran risk score. For this analysis patients will be
divided into three equal groups (that is, tertiles) accord-
ing to their Mehran risk score. Statistical analyses will be
performed with SPSS 20.0. A probability value of <0.05
is considered to indicate statistical significance and 95%
confidence intervals will be calculated.
The RIPCIN study is registered at: http://www.con-
trolled-trials.com/ISRCTN76496973.
Discussion
In this study, we hypothesize that RIPC reduces the
occurrence of CIN in patients at risk of acute kidney
injury due to the use of contrast media. A recent random-
ized pilot study suggested that RIPC reduced contrast-
induced kidney injury, however this study was performed
in patients with an unusual high risk of CIN. A comment
on this study by Mehta Oza et al. clarified that based on
the reported Mehran risk score the incidence of CIN
should lie between 26% and 30% instead of 40% as
reported by Er et al. [34]. The authors stated that this high
incidence of CIN could be attributed to a high prevalence
of heart failure and diabetes mellitus in their cohort. How-
ever, if standard measures to prevent CIN, that is, hydra-
tion with saline and discontinuation of nephrotoxic drugs,
were not carried out appropriately, then the incidence of
CIN would also be increased. As compliance to standard
preventive measures against CIN was not described by Er
et al. their results do not fully justify the conclusion that
RIPC, as an adjunct to standard preventive measures, ef-
fectively reduces CIN. Another important issue to address
is the fact that the incidence of CIN varies with the criteria
used [35]. Er et al. defined CIN as an absolute or relative
increase in serum creatinine, whereas some evidence ex-
ists that both an absolute and a relative increase in serum
creatinine more accurately predicts adverse events after
coronary angioplasty. To overcome the flaws related to
the use of different definitions of CIN, we will use the
change in serum creatinine from baseline to 48 to 72 h
after contrast administration as that primary endpoint in
the proposed trial. As serum creatinine levels generally
peak between 48 and 72 h after contrast administration, it
would be ideal to measure serum creatinine at both 48
and 72 h. However, this would not be in line with Dutch
and international guidelines which recommend checking
renal function once between 48 and 72 h after contrast ad-
ministration. In practice most patients are discharged
within 24 h after contrast administration and for many it
is already difficult to realize one blood sample between 48
and 72 h after contrast administration. In our view, it is
appropriate for proof-of-concept studies investigating new
strategies to reduce contrast-induced kidney injury to use
the change in serum creatinine from baseline to 48 to
72 h as the primary endpoint. Once the efficacy of a new
strategy against contrast-induced kidney injury has been
confirmed, much larger clinical trials should be conducted
with adverse effects after the use of contrast-media (for
example, dialysis and/or death) as the primary endpoint.
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Trial status
The trial is ongoing. Currently 61 patients have been
included.
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